LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

Solventum to Report Fourth Quarter and Full Year Fiscal 2024 Earnings on February 27, 2025

January 30, 2025 | Last Trade: US$75.37 0.23 0.31
  • Company to host an Investor Day in March 2025

ST. PAUL, Minn., Jan. 30, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal year 2024 financial results on Thursday, February 27, 2025, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2025 outlook. Other forward-looking and material information may also be discussed during the webcast.

Earnings webcast details:

Date:

Thursday, February 27, 2025

Time:

3:30 p.m. CST / 4:30 p.m. EST

Location:

https://investors.solventum.com

U.S. dial-in

+1 (800) 715-9871

International dial-in:

+1 (646) 307-1963

Conference ID:

6342275

A replay of the webcast, the earnings press release, presentation slides, and supplemental financial disclosures, will be available on the Investor Relations section of Solventum's website.

Other upcoming Investor Events:

2025 Investor Day  

Mid-March (location: NYC)

Additional details to follow

Solventum plans to host an Investor Day in March in New York City to introduce its strategy to accelerate growth and its long-range financial plan. More details and registration information will be shared soon.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page